$0.06
0.15% yesterday
Nasdaq, May 20, 09:59 pm CET
ISIN
US85209E1091
Symbol
SPRB
Sector
Industry

Spruce Biosciences Inc Stock price

$0.06
-0.06 46.45% 1M
-0.43 86.76% 6M
-0.36 84.55% YTD
-0.69 91.38% 1Y
-1.29 95.19% 3Y
-14.94 99.57% 5Y
-14.94 99.57% 10Y
Nasdaq, Closing price Tue, May 20 2025
+0.00 0.15%
ISIN
US85209E1091
Symbol
SPRB
Sector
Industry

Key metrics

Market capitalization $2.74m
Enterprise Value $-20.58m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.38
EV/Sales (TTM) EV/Sales -7.07
P/S ratio (TTM) P/S ratio 0.94
P/B ratio (TTM) P/B ratio 0.18
Revenue growth (TTM) Revenue growth -71.27%
Revenue (TTM) Revenue $2.91m
EBIT (operating result TTM) EBIT $-58.01m
Free Cash Flow (TTM) Free Cash Flow $-53.73m
Cash position $25.62m
EPS (TTM) EPS $-1.32
P/E forward negative
P/S forward 2.74
EV/Sales forward negative
Short interest 1.28%
Show more

Is Spruce Biosciences Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Spruce Biosciences Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

3 Analysts have issued a Spruce Biosciences Inc forecast:

3x Hold
100%

Analyst Opinions

3 Analysts have issued a Spruce Biosciences Inc forecast:

Hold
100%

Financial data from Spruce Biosciences Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
2.91 2.91
71% 71%
100%
- Direct Costs 0.04 0.04
67% 67%
1%
2.87 2.87
71% 71%
99%
- Selling and Administrative Expenses 14 14
5% 5%
478%
- Research and Development Expense 47 47
2% 2%
1,613%
-58 -58
13% 13%
-1,992%
- Depreciation and Amortization 0.04 0.04
67% 67%
1%
EBIT (Operating Income) EBIT -58 -58
13% 13%
-1,993%
Net Profit -55 -55
19% 19%
-1,905%

In millions USD.

Don't miss a Thing! We will send you all news about Spruce Biosciences Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Spruce Biosciences Inc Stock News

Neutral
Business Wire
14 days ago
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (OTC: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today reported financial results for the first quarter ended March 31, 2025 and provided corporate updates. “With no FDA-approved treatments currently a...
Neutral
Seeking Alpha
about one month ago
Spruce Biosciences, Inc. (NASDAQ:SPRB ) Corporate Update Conference Call April 15, 2025 8:30 AM ET Company Participants Samir Gharib - President and CFO Javier Szwarcberg - CEO Kirk Ways - Chief Medical Officer Conference Call Participants Joe Schwartz - Leerink Partners Jon Wolleben - JMP Leland Gershell - Oppenheimer Ram Selvaraju - H.C. Wainwright Operator Welcome to the Spruce Biosciences I...
Neutral
Business Wire
about one month ago
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced the company's new corporate strategy and acquisition of tralesinidase alfa enzyme replacement therapy (TA-ERT) for the treatment of S...
More Spruce Biosciences Inc News

Company Profile

Spruce Biosciences, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on developing novel therapies for rare diseases affecting the endocrine system. The company was founded in 2014 and is headquartered in Daly City, CA.

Head office United States
CEO Javier Szwarcberg
Employees 21
Founded 2014
Website www.sprucebio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today